Skip to content

Study · Not a test of the peptide alone · 1991

2 results

Suppression of growth hormone release restores phosphaturic response to PTH in immature rats.

Mulroney SE, Lumpkin MD, Haramati A

The American journal of physiology1 Dec 1991Cited by 1 (Europe PMC)

PMID1661083 (opens in a new tab)DOI10.1152/ajprenal.1991.261.6.f1110 (opens in a new tab)PepBankPUB-01661083
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Efficacy outcome

    In immature rats, 2 days of the GRF antagonist GRF-AN enhanced the phosphaturic response to PTH compared with immature control rats.

    In plain wordsIn young rats, a GRF-blocking peptide given for 2 days increased the phosphate response to PTH compared with young control rats.

    Peptide
    Sermorelin
    Outcome
    IncreasePhosphaturic response to PTH in immature rats
    Study

    ratn: not reported in source

    acutely thyroparathyroidectomized immature rat
    Comparator
    Immature control rats
    Outcome group
    Bone and joint · Kidney and urinary

    Measurements

    FEPi
    12 to 42.9%
    GRF-AN treated immature rats

    Source sentences

    Summary
    In contrast, immature rats treated for 2 days with GRF-AN (100 micrograms/kg, twice daily) displayed an enhanced phosphaturic response (FEPi from 12.0 +/- 4.2 to 42.9 +/- 3.7%, P less than 0.05) compared with immature control rats, which was not different from that observed in control adult rats.(AB…
    1 context sentence
    Summary · context
    The objective of this study was to determine whether suppression of pulsatile GH release, during administration of a synthetic peptide antagonist to GH-releasing factor, i.e., [N-acetyl-Tyr1-D-Arg2]-GRF-(1-29)-NH2 (GRF-AN), alters the renal response to increasing doses of PTH (1.5-15.0 micrograms.10…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Efficacy outcome

    The phosphaturic response of GRF-AN-treated immature rats was not different from that of control adult rats.

    In plain wordsIn young rats, after the GRF-blocking peptide, the phosphate response was like that of adult rats.

    Peptide
    Sermorelin
    Outcome
    No significant changePhosphaturic response of GRF-AN rats versus adult controls
    Study

    ratn: not reported in source

    acutely thyroparathyroidectomized immature rat
    Comparator
    Adult control rats
    Outcome group
    Bone and joint · Kidney and urinary

    Source sentences

    Summary
    which was not different from that observed in control adult rats.(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    The objective of this study was to determine whether suppression of pulsatile GH release, during administration of a synthetic peptide antagonist to GH-releasing factor, i.e., [N-acetyl-Tyr1-D-Arg2]-GRF-(1-29)-NH2 (GRF-AN), alters the renal response to increasing doses of PTH (1.5-15.0 micrograms.10…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.